| Body na spoluautora | Body za publikaci pro MU | Odkaz ISVaV | | 0,94 | 5,62 | Stanovení hyperdiploidií u mnohočetného myelomu pomocí imunofluorescenčního značení plazmatických buněk a techniky tříbarevné interfázní FISH
|
| 0,67 | 6,72 | Comparison of prognostic impact of chromosome 1q21 gain in patients with multiple myeloma treated by Velcade, thalidomide and any conventional therapy
|
| 0,00 | 0,00 | "Clinical implications of chromosomal aberrations (13q14 and 17p13 deletion, translocation t(4 |
| 0,75 | 6,72 | "Clinical implications of 13q14 and 17p13 deletion, t(4 |
| 0,67 | 6,72 | ASSOCIATION BETWEEN CHROMOSOMAL CHANGES AND STANDARD PROGNOSTIC FACTORS IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION
|
| 0,56 | 6,72 | "Do the ""new drugs"" antagonize the impact of unfavourable cytogenetic markers in multiple myeloma?"
|
| 0,67 | 6,72 | CORRELATION BETWEEN CHROMOSOMAL ABERRATIONS AND STANDARD PROGNOSTIC FACTORS IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION
|
| 1,12 | 6,72 | Genetic lesions in multiple myeloma: prognostic and predictive significance in the era of the new drugs
|
| 0,00 | 0,00 | Kompenzují nové léky vliv cytogenetických negativních prognostických markerů u pacientů s mnohočetným myelomem?
|
| 0,67 | 6,72 | Newly Diagnosed Multiple Myeloma Patients with 1q21 Amplification Treated by Autologous Stem Cell Transplantation Have Shorter Progression-Free Survival Interval
|
| 0,67 | 6,72 | Prognostic impact of 1q21 amplification in patients with multiple myeloma treated by velcade, thalidomide and any conventional chemotherapy
|
| 0,61 | 6,72 | Prognostic impact of unfavorable cytogenetic abnormalities in multiple myeloma patients treated by bortezomib (velcade)
|
| 0,61 | 6,72 | Prognostic value of selected chromosomal abnormalities in multiple myeloma patients treated by thalidomide
|
| 0,00 | 0,00 | Prognostický význam amplifikace 1q21 u pacientů s mnohočetným myelomem léčených bortezomibem (Velcade), thalidomidem (Myrin) a konvenční chemoterapií
|
| 0,37 | 4,03 | Prospective comparison of response rate and long-term results of Velcade and thalidomid based regimens
|
| 0,00 | 0,00 | Prognostic impact of 1q21 amplification for newly diagnosed and relapsed/refractory multiple myeloma patients enrolled in Brno, Czech Republic.
|
Back
(c) Michal Bulant, 2011